JP2008540434A - 鼻血を治療する組成物および方法 - Google Patents
鼻血を治療する組成物および方法 Download PDFInfo
- Publication number
- JP2008540434A JP2008540434A JP2008510151A JP2008510151A JP2008540434A JP 2008540434 A JP2008540434 A JP 2008540434A JP 2008510151 A JP2008510151 A JP 2008510151A JP 2008510151 A JP2008510151 A JP 2008510151A JP 2008540434 A JP2008540434 A JP 2008540434A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- vasoconstrictor
- bleeding
- nasal
- weight percent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000001780 epistaxis Diseases 0.000 title claims abstract description 50
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 238000000034 method Methods 0.000 title claims abstract description 7
- 208000011309 nasal bleeding Diseases 0.000 claims abstract description 32
- 239000005526 vasoconstrictor agent Substances 0.000 claims abstract description 32
- JAONZGLTYYUPCT-UHFFFAOYSA-K bismuth subgallate Chemical compound OC(=O)C1=CC(O)=C2O[Bi](O)OC2=C1 JAONZGLTYYUPCT-UHFFFAOYSA-K 0.000 claims abstract description 25
- 229960000199 bismuth subgallate Drugs 0.000 claims abstract description 24
- 208000032843 Hemorrhage Diseases 0.000 claims abstract description 16
- 230000000740 bleeding effect Effects 0.000 claims abstract description 16
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 16
- 210000003928 nasal cavity Anatomy 0.000 claims description 8
- 229960001528 oxymetazoline Drugs 0.000 claims description 8
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 6
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 claims description 6
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 claims description 6
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 6
- BYJAVTDNIXVSPW-UHFFFAOYSA-N tetryzoline Chemical compound N1CCN=C1C1C2=CC=CC=C2CCC1 BYJAVTDNIXVSPW-UHFFFAOYSA-N 0.000 claims description 6
- 229960001802 phenylephrine Drugs 0.000 claims description 5
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 5
- 235000010410 calcium alginate Nutrition 0.000 claims description 4
- 239000000648 calcium alginate Substances 0.000 claims description 4
- 229960002681 calcium alginate Drugs 0.000 claims description 4
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims description 4
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 claims description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical group CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 claims description 3
- 229930182837 (R)-adrenaline Natural products 0.000 claims description 3
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 claims description 3
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 3
- 229960002179 ephedrine Drugs 0.000 claims description 3
- 229960005139 epinephrine Drugs 0.000 claims description 3
- -1 lepodesoxyephedrine Natural products 0.000 claims description 3
- 229960005016 naphazoline Drugs 0.000 claims description 3
- 229960002748 norepinephrine Drugs 0.000 claims description 3
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 claims description 3
- 229960000395 phenylpropanolamine Drugs 0.000 claims description 3
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 3
- 229960000786 propylhexedrine Drugs 0.000 claims description 3
- JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 claims description 3
- 229960003908 pseudoephedrine Drugs 0.000 claims description 3
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 3
- 229960000337 tetryzoline Drugs 0.000 claims description 3
- 229960000833 xylometazoline Drugs 0.000 claims description 3
- 230000003639 vasoconstrictive effect Effects 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 1
- 210000001331 nose Anatomy 0.000 description 11
- 239000000843 powder Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 240000001624 Espostoa lanata Species 0.000 description 4
- 235000009161 Espostoa lanata Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002850 nasal mucosa Anatomy 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010052437 Nasal discomfort Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/29—Antimony or bismuth compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/734—Alginic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
【解決手段】本発明の組成物は、鼻出血を治療する組成物であって、次没食子酸ビスマスおよび血管収縮剤を含有する。この組成物は、鼻出血に罹っている患者に局所的に塗布したときに鼻出血を治療するのに有効である。次没食子酸ビスマスは、組成物中にて、鼻出血を止めるか遅くするのを助けるのに有効な重量パーセントで存在しており、血管収縮剤は、組成物中にて、鼻出血を止めるか遅くするのを助けるのに有効な重量パーセントで存在しており、次没食子酸ビスマスの重量パーセントおよび血管収縮剤の該重量パーセントは、鼻出血に罹っている患者に組成物を投与したときに共同して鼻出血を止めるか遅くするのを助けるのに有効である。
【選択図】なし
Description
毎日81mgのアスピリンを服用している78才の男性は、慢性的に鼻をほじる癖があり、その結果、鼻血が起こっていた。鼻腔内綿球に上記ペーストを被覆して、鼻腔内に置き、そして24時間後に取り除いたところ、出血は再発しなかった。
50才の白人女性は、発症と頻度が予測できない再発性鼻血に罹っていた。出血の範囲が確認され、そして硝酸銀を使用して焼灼された。鼻充填物を上記ペーストで被覆し、鼻腔内に置き、そして4時間後に取り除いた。粘膜反応は見られず、それ以上の出血は発生しなかった。
抗凝固治療を必要とする脳卒中歴がある58才の女性は、自宅で倒れ、鼻を折り、鼻血を出した。従来の鼻充填物を入れたが、18時間後には、鼻血を完全に抑えることができなかった。最初に入れた充填物を、上記ペーストを被覆したものに入れ替えた。この充填物を約12時間後に取り除いたところ、それ以上の出血はなかった。これらの実施例の結果は、驚くべきものであり、予想外であった。
Claims (11)
- 鼻出血を治療する組成物であって、該組成物は、次没食子酸ビスマスおよび血管収縮剤を含有し、該組成物は、鼻出血に罹っている患者に局所的に塗布したときに鼻出血を治療するのに有効であり、該次没食子酸ビスマスは、該組成物中にて、鼻出血を止めるか遅くするのを助けるのに有効な重量パーセントで存在しており、該血管収縮剤は、該組成物中にて、鼻出血を止めるか遅くするのを助けるのに有効な重量パーセントで存在しており、次没食子酸ビスマスの該重量パーセントおよび該血管収縮剤の該重量パーセントは、鼻出血に罹っている患者に該組成物を投与したときに共同して鼻出血を止めるか遅くするのを助けるのに有効である、
組成物。 - 前記組成物が、3〜99.999999重量パーセントの次没食子酸ビスマスである、請求項1に記載の組成物。
- 前記組成物が、0.00001〜20重量パーセントの血管収縮剤である、前出の請求項のいずれかに記載の組成物。
- 前記血管収縮剤が、エピネフリン、フェニレフリン、オキシメタゾリン、ノルエピネフリン、フェニルプロパノールアミン、プソイドエフェドリン、ナファゾリン、キシロメタゾリン、プロピルヘキセドリン、レポデソキシエフェドリン、エフェドリン、アドレノクロム、テトラヒドロゾリン、およびそれらの混合物からなる群から選択される、前出の請求項のいずれかに記載の組成物。
- 前記血管収縮剤が、鼻腔内塗布後にフェニレフリンが血管収縮効果を示すのと少なくとも同程度の期間にわたって血管収縮効果を示す血管収縮剤、およびそれらの混合物からなる群から選択される、前出の請求項のいずれかに記載の組成物。
- 前記血管収縮剤が、オキシメタゾリンである、前出の請求項のいずれかに記載の組成物。
- 前記組成物が、ペーストである、前出の請求項のいずれかに記載の組成物。
- 前記組成物が、さらに、アルギン酸カルシウムを含有する、前出の請求項のいずれかに記載の組成物。
- さらに、アプリケータ器具を含み、前記組成物が、該アプリケータ器具上に配置されている、前出の請求項のいずれかに記載の組成物。
- 鼻出血を治療する方法であって、鼻出血に罹っている患者に、請求項1〜8のいずれかに記載の組成物の有効量を投与する工程を包含する、方法。
- 前記投与工程が、前記組成物をアプリケータ器具上に配置して提供する工程、次いで、該アプリケータ器具を前記患者の鼻腔内に適用する工程を包含する、請求項10に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/122,894 US8304402B2 (en) | 2005-05-05 | 2005-05-05 | Composition and method for treating nosebleeds |
US11/122,894 | 2005-05-05 | ||
PCT/US2006/016922 WO2007027236A2 (en) | 2005-05-05 | 2006-05-03 | Composition and method for treating nosebleeds |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008540434A true JP2008540434A (ja) | 2008-11-20 |
JP5356806B2 JP5356806B2 (ja) | 2013-12-04 |
Family
ID=37394786
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008510151A Expired - Fee Related JP5356806B2 (ja) | 2005-05-05 | 2006-05-03 | 鼻血を治療する組成物および方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US8304402B2 (ja) |
EP (1) | EP1885347B1 (ja) |
JP (1) | JP5356806B2 (ja) |
AU (1) | AU2006285404B2 (ja) |
CA (1) | CA2606851C (ja) |
ES (1) | ES2440818T3 (ja) |
WO (1) | WO2007027236A2 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2850964C (en) | 2011-10-05 | 2021-02-02 | Jennifer L. Sanders | Methods and compositions for treating foot or hand pain |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04505267A (ja) * | 1989-05-16 | 1992-09-17 | ビレイン,ジーン | 薬物学的調製物におけるまたは関する改良点 |
JP2001513368A (ja) * | 1997-08-06 | 2001-09-04 | フォーカル,インコーポレイテッド | 止血性組織シーラント |
JP2003531850A (ja) * | 2000-04-28 | 2003-10-28 | バイオライフ,リミティド ライアビリティー カンパニー | 止血剤、血液凝固剤の塗布方法、血液凝固剤の基剤 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB335405A (en) | 1929-10-21 | 1930-09-25 | William Louis Schaaf | Improvements in suppositories for the treatment of hemorrhoids |
US4820266A (en) * | 1986-01-27 | 1989-04-11 | Berry Yale J | Method of stopping nose bleeds |
US4801454A (en) | 1986-07-17 | 1989-01-31 | The Proctor & Gamble Company | Processes for making colored pharmaceutical compositions |
US4940695A (en) | 1987-12-10 | 1990-07-10 | The Procter & Gamble Company | Bismuth-containing pharmaceutical compositions |
US5013560A (en) | 1989-03-17 | 1991-05-07 | The Procter & Gamble Company | Microbially-stable bismuth-containing liquid pharmaceutical suspensions |
US4970240A (en) * | 1989-10-18 | 1990-11-13 | Schering Corporation | Fruity flavored nasal decongestant composition |
DE19549421C2 (de) * | 1995-11-10 | 1999-11-18 | Klosterfrau Mcm Vetrieb Gmbh | Pharmazeutische Zubereitung zur Behandlung akuter Rhinitiden |
US5899918A (en) | 1998-01-23 | 1999-05-04 | Knott; Michael Mcfarland | Anatomically conforming external compression device, new use of existing noseclip device, and method of exclusively external nasal compression, for treating anterior nosebleeds |
TW460295B (en) | 1998-09-18 | 2001-10-21 | Hedonist Biochemical Technolog | Topical pharmaceutical compositions comprising bismuth subgallate and borneol for wound healing and preventing scarring and granulation |
US20020197302A1 (en) * | 1998-11-12 | 2002-12-26 | Cochrum Kent C. | Hemostatic polymer useful for rapid blood coagulation and hemostasis |
EP1587506B1 (en) | 2002-12-18 | 2008-07-23 | Algorx | Administration of capsaicinoids |
US7008392B2 (en) | 2003-06-27 | 2006-03-07 | Johnson & Johnson Consumer Companies, Inc. | Hemostatic cleansing swab |
-
2005
- 2005-05-05 US US11/122,894 patent/US8304402B2/en active Active
-
2006
- 2006-05-03 CA CA2606851A patent/CA2606851C/en active Active
- 2006-05-03 WO PCT/US2006/016922 patent/WO2007027236A2/en active Application Filing
- 2006-05-03 EP EP06824731.1A patent/EP1885347B1/en active Active
- 2006-05-03 AU AU2006285404A patent/AU2006285404B2/en not_active Ceased
- 2006-05-03 JP JP2008510151A patent/JP5356806B2/ja not_active Expired - Fee Related
- 2006-05-03 ES ES06824731.1T patent/ES2440818T3/es active Active
-
2012
- 2012-10-30 US US13/663,943 patent/US9248186B2/en active Active
-
2016
- 2016-01-18 US US14/997,786 patent/US20160128970A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04505267A (ja) * | 1989-05-16 | 1992-09-17 | ビレイン,ジーン | 薬物学的調製物におけるまたは関する改良点 |
JP2001513368A (ja) * | 1997-08-06 | 2001-09-04 | フォーカル,インコーポレイテッド | 止血性組織シーラント |
JP2003531850A (ja) * | 2000-04-28 | 2003-10-28 | バイオライフ,リミティド ライアビリティー カンパニー | 止血剤、血液凝固剤の塗布方法、血液凝固剤の基剤 |
Non-Patent Citations (3)
Title |
---|
JPN6012004942; KOTECHA,B. et al: 'Management of epistaxis: a national survey' Ann R Coll Surg Engl Vol.78, No.5, 1996, p.444-6 * |
JPN6012004945; HATTON,R.C.: 'Bismuth subgallate-epinephrine paste in adenotonsillectomies' Ann Pharmacother Vol.34, No.4, 2000, p.522-5 * |
JPN6012004948; FENTON,J.E. et al: 'Bismuth subgallate--its role in tonsillectomy' J Laryngol Otol Vol.109, No.3, 1995, p.203-5 * |
Also Published As
Publication number | Publication date |
---|---|
US20060252726A1 (en) | 2006-11-09 |
US9248186B2 (en) | 2016-02-02 |
AU2006285404B2 (en) | 2009-12-17 |
AU2006285404A1 (en) | 2007-03-08 |
CA2606851A1 (en) | 2007-03-08 |
US20160128970A1 (en) | 2016-05-12 |
EP1885347A2 (en) | 2008-02-13 |
WO2007027236A3 (en) | 2007-07-12 |
US20130052251A1 (en) | 2013-02-28 |
US8304402B2 (en) | 2012-11-06 |
EP1885347B1 (en) | 2013-10-02 |
CA2606851C (en) | 2013-11-12 |
JP5356806B2 (ja) | 2013-12-04 |
EP1885347A4 (en) | 2008-07-23 |
ES2440818T3 (es) | 2014-01-30 |
WO2007027236A2 (en) | 2007-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6495158B1 (en) | Acne patch | |
US20070026056A1 (en) | Antiviral patch | |
US20080015480A1 (en) | Hemostatic compound and its use | |
US20150283286A1 (en) | Novel hemostatic compositions and dressings for bleeding | |
BRPI9906372B1 (pt) | Composição farmaceutica aquosa para aplicação na mucosa | |
EP3074026B1 (en) | Composition, system and method for treating skin | |
US20090221984A1 (en) | Method and apparatus for providing therapeutically effective dosage formulations of lidocaine with and without epinephrine | |
CN101081308A (zh) | 壳聚糖止血剂 | |
JP2014080425A (ja) | 糖尿病性足部潰瘍を処置するための方法 | |
JP5356806B2 (ja) | 鼻血を治療する組成物および方法 | |
CN110227102A (zh) | 活血消肿药膏及其制备方法 | |
EP3248596B1 (en) | Hemostatic agent | |
US9522126B2 (en) | Treatment of skin and mucosal superficial wounds using adrenergic receptor agonists | |
TWM610166U (zh) | 微膠囊結構 | |
RU2141820C1 (ru) | Ранозаживляющая мазь "эпофен" | |
EP2117502B1 (en) | Composition for combating epistaxis | |
CN113712921A (zh) | 一种新型快速局部止痛止血剂及其应用 | |
US20100189668A1 (en) | Composition for treating herpes simplex viral infections, the method, use and process by which the composition is utilized and the manufacture of the composition | |
US20170128387A1 (en) | Treatment of Skin and Mucosal Superficial Wounds Using Adrenergic Receptor Agonists | |
RU2002134900A (ru) | Лекарственное средство и способ бесшовного лечения ран | |
JPS60178819A (ja) | 外用抗白癬菌剤 | |
NZ759509B2 (en) | Composition, system and method for treating skin | |
NZ721272B2 (en) | Composition, system and method for treating skin | |
MXPA00010447A (en) | Topical anesthetic formulation | |
JP2003300866A (ja) | 歯科用表面麻酔剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090430 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120425 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120507 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120531 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120628 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120705 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120727 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120727 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130109 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130507 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130509 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130617 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130708 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130807 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130829 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5356806 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |